IDEXX Laboratories, Inc. $IDXX Stock: Legacy Wealth Asset Management LLC Trims Holdings

Legacy Wealth Asset Management LLC decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 76.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 762 shares of the company’s stock after selling 2,503 shares during the period. Legacy Wealth Asset Management LLC’s holdings in IDEXX Laboratories were worth $398,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. J. Stern & Co. LLP grew its stake in shares of IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in IDEXX Laboratories in the 2nd quarter worth about $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in IDEXX Laboratories by 4.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after buying an additional 39,700 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of IDEXX Laboratories by 52.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after acquiring an additional 288,471 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of IDEXX Laboratories by 4.3% in the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after purchasing an additional 23,582 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.9%

Shares of IDXX opened at $518.00 on Friday. The stock has a fifty day moving average price of $538.96 and a two-hundred day moving average price of $553.07. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The company has a market cap of $40.81 billion, a price-to-earnings ratio of 36.43, a PEG ratio of 2.74 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the previous year, the company posted $3.50 EPS. IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Insider Activity

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on IDXX. Citigroup boosted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays lowered their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday. UBS Group raised their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.